IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension
Sun, Ning-L.2; Zhu, Jun-R.1; Zhao, Yanxing3; Tu, Ying-M.4; Co-Diovan Trial Investigators
关键词Chinese population Combination therapy Hydrochlorothiazide Hypertension Valsartan
刊名CURRENT MEDICAL RESEARCH AND OPINION
2008
DOI10.1185/03007990802390647
24期:10页:2863-2871
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal ; Medicine, Research & Experimental
研究领域[WOS]General & Internal Medicine ; Research & Experimental Medicine
关键词[WOS]BLOOD-PRESSURE ; JNC-VII ; MANAGEMENT ; VALSARTAN/HYDROCHLOROTHIAZIDE ; GUIDELINES ; EFFICACY ; MONOTHERAPY ; PREVALENCE ; PREVENTION ; DIFFERENCE
英文摘要

Objectives: To compare the efficacy and safety of valsartan (VAL)/ HCTZ 80/12.5 mg with VAL 80 mg in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with VAL 80 mg alone.

Research design and methods: This was a multicenter, double-blind, double-dummy, randomized, active-controlled, parallel-group trial. Patients (1175) with mild-to-moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP] >= 95 and < 110 mmHg) from 26 centers in China received VAL 80 mg o.d. for 4 weeks, 864 patients whose MSDBP remained >= 90 and < 110 mmHg were randomized (1:1) to receive VAL80/ HCTZ12.5 mg (n = 429) or VAL80 mg (n = 435) for 8 weeks.

Main outcome measures: The efficacy variable was changed from baseline to endpoint in trough MSDBP. The secondary efficacy variables were changed in mean sitting systolic blood pressure (MSSBP), response rate, and control rate.

Results: Significant reductions in MSDBP and MSSBP from baseline to endpoint were observed in both groups. There were significantly greater reductions in MSDBP (8.4 mmHg vs. 6.2 mmHg) and MSSBP (10.2 mmHg vs. 6.7 mmHg), higher response (64.2% vs. 52.5%) and control rates (53.9% vs. 40.9%) in the VAL80/HCTZ12.5 group as compared with the VAL80 group at endpoint (p < 0.001). VAL80/HCTZ12.5 was equally effective in both age subgroups (>= 65 and < 65 years) and was well tolerated. There were no deaths and the two serious adverse events reported were unrelated to study medication.

Conclusion: In Chinese patients with mild-to-moderate essential hypertension not adequately controlled by VAL 80 mg alone, VAL80/HCTZ12.5 mg combination was well tolerated and showed additional BP reduction. The limitations of this study were the inability to include an HCTZ arm as a control group and the short trial duration.

Trial registration: NCT00250562.

语种英语
WOS记录号WOS:000260261100016
资助机构Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59674
专题北京大学第二临床医学院_心血管内科
作者单位1.Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai 200032, Peoples R China
2.Beijing Univ, Peoples Hosp, Dept Cardiol, Beijing 100871, Peoples R China
3.Novartis Pharmaceut Corp, E Hanover, NJ USA
4.Beijing Novartis Pharma Co Ltd, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Sun, Ning-L.,Zhu, Jun-R.,Zhao, Yanxing,et al. Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension[J]. CURRENT MEDICAL RESEARCH AND OPINION,2008,24(10):2863-2871.
APA Sun, Ning-L.,Zhu, Jun-R.,Zhao, Yanxing,Tu, Ying-M.,&Co-Diovan Trial Investigators.(2008).Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension.CURRENT MEDICAL RESEARCH AND OPINION,24(10),2863-2871.
MLA Sun, Ning-L.,et al."Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension".CURRENT MEDICAL RESEARCH AND OPINION 24.10(2008):2863-2871.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Sun, Ning-L.]的文章
[Zhu, Jun-R.]的文章
[Zhao, Yanxing]的文章
百度学术
百度学术中相似的文章
[Sun, Ning-L.]的文章
[Zhu, Jun-R.]的文章
[Zhao, Yanxing]的文章
必应学术
必应学术中相似的文章
[Sun, Ning-L.]的文章
[Zhu, Jun-R.]的文章
[Zhao, Yanxing]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。